Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez‐Diaz, JA Perez‐Vicente… - Annals of Clinical …, 2021 - Wiley Online Library
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
[PDF][PDF] Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez-Diaz, JA Perez-Vicente… - Neurology, 2021 - researchgate.net
Objective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez‐Diaz, JA Perez‐Vicente… - Annals of Clinical …, 2021 - search.proquest.com
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
E Fernandez-Diaz, JA Perez-Vicente… - Annals of Clinical and …, 2020 - europepmc.org
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
[HTML][HTML] Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez‐Diaz, JA Perez‐Vicente… - Annals of Clinical and …, 2021 - ncbi.nlm.nih.gov
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
[PDF][PDF] Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez-Diaz, JA Perez-Vicente… - …, 2021 - scienceopen.com
Objective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population.
E Fernandez‐Diaz, JA Perez‐Vicente… - Annals of Clinical & …, 2021 - search.ebscohost.com
Objective: Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population
E Fernandez-Diaz, JA Perez-Vicente… - Annals of clinical …, 2021 - pubmed.ncbi.nlm.nih.gov
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
Real-world experience of ocrelizumab in multiple sclerosis in a Spanish population.
E Fernandez-Diaz, JA Perez-Vicente… - Annals of Clinical and …, 2020 - europepmc.org
Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …